Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | GPR183 | P32249 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GPR6 | P46095 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18498883 | 0.85 | ATM (0.47) | ATMGPR183L3MBTL1CTDSP1TDP1 | |
| SCHEMBL24762217 | 0.84 | ATM (0.43) | ATMGPR183L3MBTL1CTDSP1TDP1 | |
| SCHEMBL29764337 | 0.83 | ALDH1A1 (0.52) | GPR183PKMMEN1KMT2AALDH1A1 | |
| SCHEMBL24762614 | 0.83 | ALDH1A1 (0.52) | GPR183PKMMEN1KMT2AALDH1A1 | |
| SCHEMBL20451456 | 0.82 | TGM2 (0.49) | ATMPKM | |
| SCHEMBL27238533 | 0.80 | ATM (0.58) | ATMGPR183L3MBTL1CTDSP1TDP1 | |
| SCHEMBL29764350 | 0.78 | MAOA (0.48) | ATMGPR183L3MBTL1CTDSP1TDP1 | |
| SCHEMBL27238526 | 0.78 | MAOA (0.48) | ATMGPR183L3MBTL1CTDSP1TDP1 | |
| SCHEMBL24762218 | 0.76 | TDO2 (0.53) | PKMMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL24762684 | 0.76 | GPR183 (0.58) | GPR183PKMKMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190821-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF | TRIANA BIOMEDICINES INC (US) | 2024-06-13 | — | — | US | disclosed |
| WO-2022169755-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL) BENZENESULFONAMIDES AND USES THEREOF | TRIANA BIOMEDICINES, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
| WO-2022169755-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL) BENZENESULFONAMIDES AND USES THEREOF | TRIANA BIOMEDICINES, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190821-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF | PACSIN2, TPX2, PRSS12 | ATM 2831/4885GPR183 3074/4885L3MBTL1 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.